Literature DB >> 25500673

Genotypes of ESBL producing Escherichia coli and Klebsiella pneumoniae in relation to resistance to antimicrobial drugs.

Ana Kaftandzieva1, Elena Trajkovska-Dokic1, Vesna Kotevska1, Zaklina Cekovska1, Gordana Jankoska1.   

Abstract

UNLABELLED: The aim of the study was to evaluate the association of drug resistance with β-lactamase gene types in ESBL positive E. coli and Klebsiella pneumoniae-Kp.
MATERIAL AND METHODS: A total of 251 ESBL-positive E. coli and Kp isolates obtained from urine, tracheal aspirate, wound swab and blood from patients hospitalised at the University Clinics in Skopje were detected using the ESBL set and automated Vitek 2 system. Vitek was also used for susceptibility testing (determination of MIC of 17 antimicrobial agents). Multiplex PCR was used to identify genes for different types of ESBLs in a 100 randomly selected, ESBL positive strains.
RESULTS: More of the 87 ESBL typeable isolates (61%) harbour two or more bla genes and the frequency of antibiotic resistance was high in these isolates, compared to those with a single gene. Isolates with ≥ 3 genes were highly resistant to beta-lactams and non-beta lactams used. The degree of resistance to 3 rd generation cephalosporins was also high in these isolates (MIC ≥ 64). More of the ESBL-positive isolates showed higher resistance to cefotaxime than to ceftazidime.
CONCLUSION: Identification of the genes is necessary for the surveillance of their transmission in hospitals. Surveillance of antibiotic resistance patterns are crucial to overcome the problems associated with ESBLs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25500673     DOI: 10.2478/prilozi-2014-0004

Source DB:  PubMed          Journal:  Pril (Makedon Akad Nauk Umet Odd Med Nauki)        ISSN: 1857-9345


  1 in total

1.  Detection of multi-drug resistant Escherichia coli in the urban waterways of Milwaukee, WI.

Authors:  Anthony D Kappell; Maxwell S DeNies; Neha H Ahuja; Nathan A Ledeboer; Ryan J Newton; Krassimira R Hristova
Journal:  Front Microbiol       Date:  2015-04-29       Impact factor: 5.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.